Research notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

3Q25 update

Challenger Financial Svcs
3:27pm
April 17, 2025
CGF has released its 3Q25 update. The key takeaway, in our view, was CGF has narrowed its FY25 NPAT guidance range to A$450m-A$465m (previously A$440m-A$480m), which indicates increased confidence with the current year outlook. We make relatively nominal changes to our CGF FY24F/FY25F EPS of ~-1%/-2%. Our PT rises to A$7.51, with our earnings changes offset by a valuation roll-forward. We think CGF has shown good earnings momentum in recent periods (3 year NPAT CAGR +11%), and with the stock trading on an undemanding ~11x FY25F PE multiple, we see further upside. ADD maintained.

1H25 earnings beat, FY26 ROE target offers upside

Bank of Queensland
3:27pm
April 16, 2025
1H25 EPS and DPS growth beat expectations. BOQ stands firm on its FY26 ROE and CTI targets, offering material upside to our upgraded forecasts and a potential valuation of >$10/sh if they are achieved. Our base case is more conservative, hence we retain a HOLD with 12 month potential TSR of c.8% at current prices. Upgraded cash EPS by 3%/6%/9% for FY25/26/27F, as we downgrade our NIM forecast, upgrade asset base growth (stronger loan growth), and reduce LIE (lower-for-longer). DCF valuation lifts 1% to $7.04/sh, as the earnings upgrade is offset by higher CET1 investment to meet the growth in RWA. Potential >$10/share valuation based on application of a P:BV vs ROE peer group regression.

Steel market pain helps Pilbara transition

Rio Tinto
3:27pm
April 16, 2025
As expected a softer start with a weather-impacted 1Q25 Pilbara performance. Copper was a bright spot coming in ahead as OTUG continues to shine. We continue to see RIO as trading below value while offering appealing relative safety in current dynamic market conditions. Maintain ADD rating, A$123 PT.

Highly leveraged to continued gold price strength

Evolution Mining
3:27pm
April 15, 2025
EVN delivered another strong production and cash flow result. Deleveraging continued at a rapid pace with net debt reducing 25% qoq and gearing now at ~19%. Strong cash flows give way to accelerated repayments of EVN’s term loans which will assist in an even more rapid deleveraging. We maintain our Hold rating with a A$8.00ps TP (previously A$5.90ps).

Partnership to bring Sports Direct Down Under

Accent Group
3:27pm
April 15, 2025
After much media speculation and following the initial strategic investment from UK retailer Frasers Group (FRAS.LSE) in August 2024, AX1 today announced it has made a long term agreement to roll out stores under Frasers’ flagship brand Sports Direct in Australia and New Zealand. The long term agreement will see AX1 rollout at least 50 stores over the next 6 years with an aspirational target of 100 stores in time. Frasers Group will increase its shareholding in AX1 to 19.57% (from 14.57%) via a placement of 35.2m shares at $1.718 per share (a 3.5% discount to Friday’s close). Proceeds from the placement ($60.4m) will be used to fund the initial roll-out of Sports Direct. AX1’s CEO, Daniel Agostinelli, has committed to remaining as CEO for at least another 3 years. We have lowered our EPS by 3% in FY25 and 2% in FY26. We have included a modest contribution for Sports Direct rollout into FY26/27. We have retained our HOLD recommendation, with a $2.00 price target, down from $2.20.

FDA approval- revolutionising heart failure treatment

EBR Systems
3:27pm
April 15, 2025
Despite what appears to be tumultuous time at US regulatory agencies, EBR delivered on its timeline and has received FDA’s blessing for its cardiac resynchronisation therapy (CRT) system (known as WiSE) for the treatment of heart failure, a major milestone after more than two decades in development. Encouragingly, contraindications are limited and the label aligns with the initially targeted cUS$3.6bn key market segments, including use with leadless pacemakers, with investor concern that Abbott’s Aveir was excluded, pending additional data, misplaced, in our view. We also believe the post-marketing study should not be viewed with any apprehension, as it is merely par for the course and in fact, should help strengthen the use case and label expansions over time. We continue to view commercial and manufacturing readiness, along with a reimbursement path that is both streamlined and incentivised, as helping to smooth the transition from developmental stage into a commercially viable medical device business. We make no changes to CY25-26 forecasts, and maintain our A$2.86 DCF-based valuation. With clinical risk now mitigated we move to an Add rating (from Speculative Buy).

1Q25 update

MA Financial Group
3:27pm
April 14, 2025
MAF has released its 1Q25 update. This showed that momentum is still generally reasonable across the MAF franchise in our view.  In summary, whilst Asset Management net flows were a bit below our expectations, MA Money lending growth was better than we expected. We downgrade our MAF FY25F/FY26F EPS by 4%-7% on lower Asset Management net inflows and AUM forecasts. Our PT is reduced to A$8.11 (previously A$8.92). We think MAF management are building a strong, differentiated franchise. We maintain our ADD recommendation, with significant upside existing to our price target.

Collateral damage

Reliance Worldwide
3:27pm
April 14, 2025
RWC’s share price has fallen 12% since the beginning of April and 23% over the past 3 months as uncertainty continues in relation to US tariffs on Chinese goods. US tariffs on Chinese goods (except certain consumer electronics) currently stands at 145%, although given recent history, this can turn on a dime and could depend on whether President Trump and President Xi can reach a deal. RWC predominantly manufactures key products in each region for sale within that region. However, cost of goods sold (COGS) for its Americas division includes ~US$120m in purchases from China that are subject to tariffs. We provide a scenario analysis on the impact on FY26F EBITDA for varying levels of US tariffs on Chinese goods against RWC’s ability to offset. Due to the highly uncertain outlook, we move our rating on RWC to Hold (from Add) as we await further clarity on tariffs and what this could mean for operating costs as well as revenue given risks to the global macroeconomic backdrop. We make no changes to EBITDA in FY25F but decrease both FY26F and FY27F by 7%. Our target price declines to $4.15 (from $5.80 previously).

Truly ground breaking moment

Imricor Medical Systems
3:27pm
April 13, 2025
The medical team at Amsterdam University Medical Centre have performed the first-in-human ventricular ablation guided by real time interventional cardiac magnetic resonance (iCMR) with IMR’s technology including its NorthStar mapping system. This has been a 20 year journey by IMR’s founder Steve Wedan and his team and marks a truly ground breaking moment in medical history. Following the recent A$70m capital raise, IMR is in a strong financial position to achieve a number of key catalysts including the approval of the NorthStar mapping system in Europe and US, secure approval in the US for atrial flutter, complete the Europe trail for ventricular tachycardia and drive sales in Europe and Middle East. We have made no changes to forecasts or our target price of A$2.28. IMR is a key pick in the emerging healthcare space and we maintain our speculative buy recommendation.

Strategic acquisitions make sense

Ebos Group
3:27pm
April 11, 2025
EBO is raising A$250m to help fund two strategic acquisitions; one in the NZ animal care market and the other completing full ownership of a SE Asian medical distributor. The acquisitions make sense and are being purchased on reasonable multiples. We have updated our model which results in a small valuation upgrade to A$39.15 (was A$38.56). Although the markets are uncertain we think EBO offers investors a company with a defensive earnings profile. We maintain an Add recommendation.

News & insights

Michael Knox, Chief Economist explains how the RBA sets interest rates to achieve its 2.5% inflation target, predicting a cash rate reduction to 3.35% by November when inflation is expected to reach 2.5%, based on a historical average real rate of 0.85%.


There is more to what happened at Jackson Hole than just the speech by Jay Powell.

In my talk last week ,I said that our model of the Fed funds rate stood at 3.65%. This is actually 70 basis points lower than the actual  level of 4.35%.

I also said that the Fed was successfully achieving a "soft landing" with employment growing at 1%. This was below the median level of employment growth  since 2004 of 1.6%.

Still , as I listened to Jay Powell Speak , I noted a sense of concern in his voice when he said that "The July employment report released earlier this month slowed to an average pace of only 35,000 average per month over the past three months, down from 168,000 per month during 2024. This slowdown is much larger than assessed just a month ago."

My interpretation of this is that Chair Powell may be concerned that the "soft landing " achieved by the Fed may be in danger of turning into a "hard landing". This suggested a rate cut of 25 basis points by the Fed at the next meeting on 17-18 September.

This would leave the Fed Funds rate at 4.1%. This would mean that the Fed Funds rate would still be 45 basis points higher than our model estimate of 3.65%. Hence the Fed Funds rate would remain "modestly restrictive."

Dire Demography?

Jackson Hole was actually a Fed Strategy meeting with many speakers in addition to Jay Powell.

Two speakers who followed on the  afternoon of his speech were Claudia Goldin, Professor at Harvard

and Chad Janis of Stanford Graduate Business School. They each gave foreboding presentations on the demography of developed economies.

Claudia Goldin spoke on "The Downside of Fertility".  She noted that birth rates in the Developed World are now generally  below replacement level. The Total Fertility rate is below 2 in France , the US and the UK.

It is dangerously low below 1.5 in Italy and Spain and below 1 in Korea. She observes that the age of first marriage of couples  in the US is now 7 years later than it was in the 1960's. This reduces  their child bearing years.

This paper was then followed by a discussion of it by Chad Janis of Stanford Graduate Business School. He noted that there is a profound difference between a future with a replacement rate of 2.2 kids per family , which he called  the "Expanding Cosmos"  with

•   Growing population leading to a growing number of researchers, leading to rising living standards  and Exponential growth in both living standards and population AND a replacement level of 1.9 kids per family which leads to  

•   Negative population growth , which he called "an Empty Planet " and the end of humanity

 as numbers of researchers declines and economic growth ceases.

Of course this seems all  very serious indeed .  Perhaps what this really means ,is that  if  we want to save the world , we should just relax and start having a lot more fun!!

Read more
Michael Knox, Chief Economist explains how the RBA sets interest rates to achieve its 2.5% inflation target, predicting a cash rate reduction to 3.35% by November when inflation is expected to reach 2.5%, based on a historical average real rate of 0.85%.

Today, we’re diving into how the Reserve Bank of Australia (RBA) sets interest rates as it nears its target of 2.5% inflation, and what happens when that target is reached. Back in 1898, Swedish economist Knut Wicksell  published *Money, Interest and Commodity Prices*, introducing the concept of the natural rate of interest. This is the real interest rate that maintains price stability. Unlike Wicksell’s time, modern central banks, including the RBA, focus on stabilising the rate of inflation rather than the price level itself.

In Australia, the RBA aims to keep inflation at 2.5%. To achieve this, it sets a real interest rate, known as the neutral rate, which can only be determined in practice by observing what rate stabilises inflation at 2.5%. Looking at data from January 2000, we see significant fluctuations in Australia’s real cash rate, but over the long term, the average real rate has been 0.85%. This suggests that the RBA can maintain its 2.5% inflation target with an average real cash rate of 0.85%. This is a valuable insight as the RBA approaches this target.

Australian Real Cash Rate -July 2025

As inflation nears 2.5%, we can estimate that the cash rate will settle at 2.5% (the inflation target) plus the long-term real rate of 0.85%, resulting in a cash rate of 3.35%. At the RBA meeting on Tuesday, 12 August, when the trimmed mean inflation rate for June had already  dropped to 2.7%, the RBA reduced the real cash rate to 0.9%, resulting in a cash rate of 3.6%.

We anticipate that when the trimmed mean inflation for September falls to 2.5%, as expected, the cash rate will adjust to 2.5% plus the long-term real rate of 0.85%, bringing it to 3.35%. The September quarter trimmed mean will be published at the end of October, just before the RBA’s November meeting. We expect the RBA to hold the cash rate steady at its September meeting, but when it meets in November, with the trimmed mean likely at 2.5%, the cash rate is projected to fall to 3.35%.

Australian Real Cash Rate - August 2025
Read more
Michael Knox, Chief Economist looks at what might have happened in January 2026 if the cuts in corporate tax rates in Trumps first term were not renewed and extended in the One Big Beautiful Bill

In recent weeks, a number of media commentators have criticized Donald Trump's " One big Beautiful Bill " on the basis of a statement by the Congressional Budget Office that under existing legislation the bill adds $US 3.4 trillion to the US Budget deficit. They tend not to mention that this is because the existing law assumes that all the tax cuts made in 2017 by the first Trump Administration expire at the end of this year.

Let’s us look at what might have happened in January 2026 if the cuts in US corporate tax rates in Trumps first term were not renewed and extended in the One Big Beautiful Bill.

Back in 2016 before the first Trump administration came to office in his first term, the US corporate tax rate was then 35%. In 2017 the Tax Cut and Jobs Act reduced the corporate tax rate to 21%. Because this bill was passed as a "Reconciliation Bill “, This meant it required only a simple majority of Senate votes to pass. This tax rate of 21% was due to expire in January 2026.

The One Big Beautiful Bill has made the expiring tax cuts permanent; this bill was signed into law on 4 July 2025. Now of course the same legislation also made a large number of individual tax cuts in the original 2017 bill permanent.

What would have happened if the bill had not passed. Let us construct what economists call a "Counterfactual"

Let’s just restrict ourselves to the case of what have happened in 2026 if the US corporate tax had risen to the prior rate of 35%.

This is an increase in the corporate tax rate of 14%. This increase would generate a sudden fall in US corporate after-tax earnings in January 2026 of 14%. What effect would that have on the level of the S&P 500?

The Price /Earnings Ratio of the S&P500 in July 2025 was 26.1.

Still the ten-year average Price/ Earnings Ratio for the S&P500 is only 18.99. Let’s say 19 times.

Should earnings per share have suddenly fallen by 14%, then the S&P 500 might have fallen by 14% multiplied by the short-term Price/ Earnings ratio.

This means a likely fall in the S&P500 of 37%.

As the market recovered to long term Price Earnings ratio of 19 this fall might then have ben be reduced to 27%.

Put simply, had the One Big, beautiful Bill not been passed, then in 2026 the US stock market might suddenly have fallen by 37% before then recovering to a fall of 27% .

The devastating effect on the US and indeed World economy might plausibly have caused a major recession.

On 9 June Kevin Hassert the Director of the National Economic Council said in a CBS interview with Margaret Brennan that if the bill did not pass US GDP would fall by 4% and 6-7 million Americans would lose their jobs.

The Passage of the One Big Beautiful Bill on 4 July thus avoided One Big Ugly Disaster.

Read more